Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 4/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | GHSR | Q92847 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30682966 | 0.86 | UCHL1 (0.43) | UCHL1NR1H2DDB1CRBN | |
| SCHEMBL24495434 | 0.86 | UCHL1 (0.43) | UCHL1NR1H2DDB1CRBN | |
| SCHEMBL29608082 | 0.85 | UCHL1 (0.55) | UCHL1NR1H2DDB1CRBNGPR119 | |
| SCHEMBL29607370 | 0.85 | UCHL1 (0.55) | UCHL1NR1H2DDB1CRBNGPR119 | |
| SCHEMBL17681742 | 0.85 | UCHL1 (0.55) | UCHL1NR1H2DDB1CRBNGPR119 | |
| SCHEMBL17681690 | 0.85 | UCHL1 (0.55) | UCHL1NR1H2DDB1CRBNGPR119 | |
| SCHEMBL17681740 | 0.85 | UCHL1 (0.55) | UCHL1NR1H2DDB1CRBNGPR119 | |
| SCHEMBL29607737 | 0.85 | UCHL1 (0.55) | UCHL1NR1H2DDB1CRBNGPR119 | |
| SCHEMBL30557078 | 0.84 | DRD1 (0.43) | UCHL1NR1H2DDB1CRBNGHSR | |
| SCHEMBL33532209 | 0.84 | UCHL1 (0.42) | UCHL1NR1H2DDB1CRBNGHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107001278-B | Tetrahydroisoquinoline derivatives | UCB生物制药私人有限公司 | 2020-11-24 | — | — | CN | disclosed |
| EP-3204359-B1 | TETRAHYDROISOQUINOLINE DERIVATIVES | UCB Biopharma SRL (BE) | 2020-07-01 | — | — | EP | disclosed |
| EP-3204359-B1 | TETRAHYDROISOQUINOLINE DERIVATIVES | UCB Biopharma SRL (BE) | 2020-07-01 | — | — | EP | disclosed |
| US-10105359-B2 | Tetrahydroisoquinoline derivatives | UCB BIOPHARMA SPRL (BE) | 2018-10-23 | — | — | US | disclosed |
| US-20170304292-A1 | Tetrahydroisoquinoline Derivatives | UCB BIOPHARMA SPRL (BE) | 2017-10-26 | — | — | US | disclosed |
| US-20170304292-A1 | Tetrahydroisoquinoline Derivatives | UCB BIOPHARMA SPRL (BE) | 2017-10-26 | — | — | US | disclosed |
| US-6277861-B1 | FOR TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISORDERS, PSYCHOLOGICAL DISORDERS, MUSCULAR DISORDERS, DRUG ADDICTION WITHDRAWAL, PAIN | SMITHKLINE BEECHAM, P.L.C. (GB) | 2001-08-21 | — | — | US | disclosed |
| EP-0971897-A1 | ANTI-CONVULSANT ISOQUINOLYL-BENZAMIDE DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998041507-A1 | ANTI-CONVULSANT ISOQUINOLYL-BENZAMIDE DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 1998-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170304292-A1 | Tetrahydroisoquinoline Derivatives | OPRD1, ADRA1D, GPR52 | UCHL1 4153/4885NR1H2 96/4885HDAC1 1485/4885 |
| US-10105359-B2 | Tetrahydroisoquinoline derivatives | OPRD1, ADRA1D, GPR52 | UCHL1 4153/4885NR1H2 96/4885HDAC1 1485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.